Metaxalone: profile and news

King Pharmaceuticals Reports Year-End and Fourth-Quarter 2005 ... Feb 28, 2006
Inventory levels of Skelaxin(R) (metaxalone) and Altace(R) (ramipril) were each slightly higher than one month of estimated end-user demand as of the end of ... - Black Enterprise,

Pain Therapeutics and King Pharmaceuticals Receive Special ... Feb 16, 2006
...people. King's growing line of branded products includes neuroscience drugs such as Skelaxin® (metaxalone) and Sonata® (zaleplon). ... - Yahoo! News (press release)

Murder defendant indicted on new charge Jan 11, 2006
...other counts for possessing the controlled substances of Oxycodone and Acetaminophen, Alprazolam, Penicillin, Hydrochlorothiazide, and Metaxalone without a ... - Clarke Times Courier,

King Pharmaceuticals Announces Cross-License Agreement with Mutual ... Dec 10, 2005
...the parties has granted the other a worldwide license to certain intellectual property, including patent rights and know-how, relating to metaxalone, a press ... - ag-IP-news Agency,

King Pharmaceuticals Reports Third-Quarter 2005 Financial Results Nov 9, 2005
...and approximately $11.0 million of the Company's co-promotion expense related to net sales of Altace(R). Net sales of Skelaxin(R) (metaxalone) increased 92% to ... - PR Newswire (press release),

King Pharmaceuticals Reports Third-Quarter 2005 Financial Results Nov 9, 2005
Net sales of Skelaxin® (metaxalone) increased 92% to $115.9 million during the third quarter of 2005 from $60.4 million during the same period of the prior ... - Yahoo! News (press release)

King Pharmaceuticals Reports Second-Quarter 2005 Financial Results Sep 9, 2005
Net sales of Skelaxin(R) (metaxalone) increased 71% to $86.8 million during the second quarter of 2005 from $50.9 million during the same period of the prior ... - Investor's Business Daily (subscription)

King Pharmaceuticals Appoints Joseph Squicciarino Chief Financial ... Jun 1, 2005
...strategies that result in growth in net sales of King's products, including, but not limited to, Altace(R) (ramipril), Skelaxin(R) (metaxalone), Levoxyl(R ... - PR Newswire (press release)

King Pharmaceuticals Reports First-Quarter 2005 Financial Results May 9, 2005
31, 2005, as compared to the same period of the prior year, particularly with respect to Altace(R) (ramipril) and Skelaxin(R) (metaxalone), and significantly ... - PR Newswire

King Pharmaceuticals Completes Wholesale Inventory Reductions May 3, 2005
Product Wholesale Inventory Wholesale Inventory as of as of December 31, 2004 March 31, 2005 Altace(R) (ramipril) 1.7 0.9 Skelaxin(R) (metaxalone) 1.1 0.9 ... - PR Newswire

King Pharmaceuticals Repositioned for Growth Feb 28, 2005
...including, but not limited to, Altace(R), Thrombin-JMI(R) (thrombin, topical, bovine, USP), Sonata(R) (zaleplon), Skelaxin(R) (metaxalone), and Levoxyl(R ... - PR Newswire (press release)

Other information

Indication
For the treatment of painful musculoskeletal conditions

Pharmacology
Metaxalone is a skeletal muscle relaxant indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions. The mode of action of this drug has not been clearly identified, but may be related to its sedative properties. Metaxalone does not directly relax tense skeletal muscles in man.

Mechanism Of Action
The mechanism of action of metaxalone in humans has not been established, but may be due to general central nervous system depression.

Drug Category
Muscle Relaxants, skeletal muscle; Analgesics; Hypnotics and Sedatives;

Brand Names/Synonyms
.Meta.Xalon; .Meta.Xalone; .Meta.Zalone; .Meta.Zolone; AHR 438; AHR-438; HSDB 3236; Metassalone [Dcit]; Metaxalon; Metaxalona [Inn-Spanish]; Metaxalona [Spanish]; Metaxalone; Metaxalone [Usan:Ban:Inn]; Metaxalonum [Inn-Latin]; Metaxalonum [Latin]; Metazalone; Metazolone; Methaxalonum; Methoxolone; Skelaxin; Zorane

Dosage Forms
Tablet

Absorption
Not Available

Interactions
Interactions for Metaxalone:

SKELAXIN may enhance the effects of alcohol, barbiturates and other CNS depressants.

Chemical IUPAC Name
5-[(3,5-dimethylphenoxy)methyl]oxazolidin-2-one

Chemical Formula
C12H15NO3

Half Life
9.2 (+/- 4.8) hours

Drug Type
Approved Drug

# Accession No
APRD00514

CAS Registry Number
1665-48-1